$ENLV From the Enlivex Business Update: Sepsis: Due to the impact of COVID-19 pandemic on trial enrollment to-date, and the potential impact on enrollment going forward, Enlivex currently expects that interim results from the trial will be reported in the first half of 2022, and top-line data will be reported by year-end 2022. Covid: The enrollment of patients into the study in multiple Israeli sites to-date has been slower than originally anticipated, mainly due to the successful and swift control of COVID-19’s spread by the Israeli health authorities, which has resulted in reduced numbers of severe and critical COVID-19 patients. Enrollment in the trial is projected to increase following the initiation of sites in Europe, which has recently seen an increase of COVID-19 infections. Enlivex currently expects that top-line data from the trial will be available in late 2022 or Q1 of 2023.
2